Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

Denali Therapeutics (DNLI.O) said on Thursday its partner Sanofi (SASY.PA) has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals.